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Renoprotective Effects of a Highly Selective A3 Adenosine 
Receptor Antagonist in a Mouse Model of Adriamycin-induced 
Nephropathy
The concentration of adenosine in the normal kidney increases markedly during renal 
hypoxia, ischemia, and inflammation. A recent study reported that an A3 adenosine 
receptor (A3AR) antagonist attenuated the progression of renal fibrosis. The adriamycin 
(ADX)-induced nephropathy model induces podocyte injury, which results in severe 
proteinuria and progressive glomerulosclerosis. In this study, we investigated the preventive 
effect of a highly selective A3AR antagonist (LJ1888) in ADX-induced nephropathy. Three 
groups of six-week-old Balb/c mice were treated with ADX (11 mg/kg) for four weeks and 
LJ1888 (10 mg/kg) for two weeks as following: 1) control; 2) ADX; and 3) ADX + LJ1888. 
ADX treatment decreased body weight without a change in water and food intake, but this 
was ameliorated by LJ1888 treatment. Interestingly, LJ1888 lowered plasma creatinine 
level, proteinuria, and albuminuria, which had increased during ADX treatment. 
Furthermore, LJ1888 inhibited urinary nephrin excretion as a podocyte injury marker, and 
urine 8-isoprostane and kidney lipid peroxide concentration, which are markers of 
oxidative stress, increased after injection of ADX. ADX also induced the activation of 
proinflammatory and profibrotic molecules such as TGF-β1, MCP-1, PAI-1, type IV 
collagen, NF-κB, NOX4, TLR4, TNFα, IL-1β, and IFN-γ, but they were remarkably 
suppressed after LJ1888 treatment. In conclusion, our results suggest that LJ1888 has a 
renoprotective effect in ADX-induced nephropathy, which might be associated with 
podocyte injury through oxidative stress. Therefore, LJ1888, a selective A3AR antagonist, 
could be considered as a potential therapeutic agent in renal glomerular diseases which 
include podocyte injury and proteinuria.
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INTRODUCTION
Adenosine is well known to have a cell protective effect in stress-
ful situations, such as ischemia, hypoxia, and inflammation (1). 
It is released from metabolically active cells into the extracellu-
lar space and is produced by the breakdown of released ade-
nosine triphosphate (ATP). While the concentration of extracel-
lular adenosine is about 300 nM in normal cells (2), its concen-
trations rapidly exceed 1 μM in cells undergoing damage (3). 
Adenosine’s regulation of tissue function is mediated through 
activation of a family of 4 G-protein coupled receptors, which 
includes the A1, A2a, A2b, and A3 adenosine receptors (AR). 
Concentrations of extracellular adenosine vary widely depend-
ing on external factors and the degree of stress, tissue types, and 
activation levels of the 4 adenosine receptors (4). Previous stud-
ies investigating the role of adenosine have focused on the ago-
nists and antagonists of adenosine receptors instead of adenos-
ine itself, because of the limitation of its very short half-life (5).
 The A3 adenosine receptor (A3AR) has been detected in a 
wide variety of tissues. A3AR was highly expressed in the testis, 
but was less likely to be expressed in the lungs, kidney, heart, 
and central nervous system. Interestingly, inflammatory and 
cancer cells possess higher A3AR content than other adenosine 
receptor subtypes. A3AR is able to play a different roles under 
ischemic conditions, where it shows pro/anti-inflammatory, 
cellular proliferation/death, and pro/antitumoral effects de-
pending on different pathophysiological environments (6). Pre-
vious studies demonstrated that inhibition of A3AR leads to kid-
ney protection in ischemia-reperfusion injury (7) and myoglo-
binuria-induced injury (8). A recent study reported that A3AR 
antagonist ameliorates the progression of tubulointerstitial fi-
brosis in a unilateral ureteral obstruction (UUO) mice model (9). 
 Few reports have described the expression and distribution 
of adenosine receptor subtypes in the kidney and the role of 
A3AR and A3AR antagonists in kidney injury. A new A3AR an-
tagonist (LJ1888) may be a powerful, highly selective, species-
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independent, and orally available agent (10). However, there is 
rare data for the role of A3AR in glomerular kidney injury. The 
aim of this study was to investigate the mechanism and reno-
protective effects of the highly selective A3AR antagonist (LJ1888) 
in adriamycin (ADX)-induced nephropathy.
MATERIALS AND METHODS
Experimental animals
All 6-week-old Balb/c male mice weighing 22-24 g were purcha-
sed from RaonBio Co. (Yongin, Korea). They were randomly as-
signed to three groups: control (n = 5); ADX injection (n = 10); 
or administration of LJ1888 after ADX injection (n = 10). Mice 
received a single tail vein injection of ADX diluted with 0.9% sa-
line to a final dose of 11 mg/kg. Control mice received the same 
volume of isotonic saline. Four weeks after ADX injection, mice 
drank water mixed with 10 mg/kg per day of LJ1888 (Lee et al. 
[9] College of Pharmacy, Ewha Womans University, Seoul, Ko-
rea) for two weeks as previously described. All mice were pro-
vided with a standard diet and water, and were maintained at 
constant temperature (23°C ± 2°C) and humidity (55% ± 5%) 
with a 12-hour light/dark cycle. Daily food intake was monitored 
at regular intervals to confirm drug administration. Plasma cre-
atinine level was determined using high-performance liquid 
chromatography. To determine urinary protein, albumin, and 
nephrin excretion, mice were caged individually and a 24-hour 
urine sample was collected at baseline, two, four and six weeks. 
Urinary albumin concentrations were determined with a com-
petitive enzyme linked immunosorbent assay (ELISA) kit (ALP-
CO, Westlake, OH, USA). Urinary protein concentrations were 
determined by colorimetric detection using bicinchoninic acid 
(Pierce BCA protein Assay Kit, Pierce Biotech. Inc., Rockford, 
IL, USA). Urinary nephrin measurement was performed with 
the commercially available ELISA kit (Exocell, Philadelphia, PA, 
USA). The urinary 8-isoprostane level was measured using an 
ELISA kit (Cayman Chemical, Ann Arbor, MI, USA). The extent 
of peroxidative reaction in the kidney tissue was determined by 
direct measurement of lipid hydroperoxides (LPO) using an 
LPO assay kit (Cayman Chemical), as described previously (11). 
Mice were sacrificed under anesthesia with intraperitoneal in-
jections of sodium pentobarbital (50 mg/kg). Their heart, epi-
didymal fat, liver, and kidney tissues were extracted and subse-
quently snap-frozen in liquid nitrogen.
Analysis of gene expression by real-time quantitative 
polymerase chain reaction
We extracted total RNA from experimental cells using the Trizol 
reagent. Primers were designed for their respective gene sequen-
ces using the Primer 3 software, and the secondary structures of 
the templates were examined and excluded using the mfold 
program (Supplementary Table 1). Quantitative gene expres-
sion was performed using a Light Cycler 1.5 system (Roche Di-
agnostics Corporation, Indianapolis, IN, USA) using SYBR Green 
technology. In 96-well real-time polymerase chain reaction 
(PCR) plates, 10 μL SYBR Green master mix was added to 1 μL 
of RNA (corresponding to 50 ng of total RNA) and 900 nM of 
forward and reverse primers for a total reaction volume of 20 
μL. Real-time reverse transcriptase PCR was performed for 10 
minutes at 50°C and for 5 minutes at 95°C. Thirty PCR cycles of 
denaturation for 10 seconds at 95°C and annealing with exten-
sion for 30 seconds at 60°C were then conducted. Gene level ra-
tios relative to β-actin (relative gene expression number) were 
calculated by subtracting the threshold cycle number of the tar-
get gene from that of β-actin and squaring this difference. We 
evaluated the specificity of each PCR product using melting 
curve analysis, followed by agarose gel electrophoresis. 
Protein extraction and western blot analysis
Nuclear and cytoplasmic proteins were extracted from renal 
cortical tissues and cells using a commercial nuclear extraction 
kit according to the manufacturer’s instructions (Active Motif, 
Carlsbad, CA, USA). Protein concentration was determined us-
ing the bicinchoninic acid method (Pierce Pharmaceuticals). 
For western blotting, 40 μg protein was electrophoresed on a 
10% SDS-PAGE mini-gel. Proteins were transferred onto a poly-
vinylidene difluoride membrane, and the membrane was hy-
bridized in blocking buffer overnight at 4°C with mouse mono-
clonal anti-nuclear factor (NF)-κB p65 antibody (1:1,000; Cell 
Signaling Technology, Danvers, MA, USA), rabbit polyclonal 
anti-transforming growth factor (TGF)-β1 antibody (1:200; San-
ta Cruz Biotechnology, Santa Cruz, CA, USA), rabbit polyclonal 
anti-nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase 4 (NOX4) antibody (1:500; Novus Biologicals, Littleton, 
CO, USA) and goat polyclonal anti-toll-like receptor 4 (TLR4) 
antibody (1:500; Santa Cruz Biotechnology). The membrane 
was subsequently incubated with horseradish peroxidase-con-
jugated secondary antibody (1:1,000 dilution) for 60 minutes at 
room temperature. We detected the specific signals using an 
enhanced chemiluminescence method (Amersham, Bucking-
hamshire, UK).
Histological examination and immunohistochemistry
Kidney samples were fixed in 10% buffered formalin and em-
bedded in paraffin. Kidney tissue was cut into 4-µm-thick slices 
and stained with periodic acid Schiff (PAS), Masson’s trichrome, 
and sirius red staining. Macrophage infiltration was detected by 
rat anti-mouse F4/80 antibody (1:2,000; Serotec, Raleigh, NC, 
USA) and incubated at room temperature for 1 hour, followed 
by use of the Envision kit (Dako, Carpinteria, CA, USA). To per-
form immunohistochemical staining for type I collagen, TGFβ1, 
and α-smooth muscle actin (SMA), kidney sections were trans-
ferred to a 10 mM/L citrate buffer solution adjusted to a pH of 
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6.0. Thereafter, sections were microwaved for 10–20 minutes to 
retrieve antigens for TGFβ1 and α-SMA, or treated with trypsin 
(Sigma, St. Louis, MO, USA) for 30 minutes at 37°C for type I 
collagen and type IV collagen. To block endogenous peroxidase 
activity, 3.0% H2O2 in methanol was applied for 20 minutes, fol-
lowed by incubation at room temperature for 60 minutes with 
3% BSA/3% normal goat serum. Slides were incubated over-
night at 4°C with rabbit polyclonal anti-TGF-β1 antibody and 
rabbit polyclonal anti-type I collagen antibody (1:200; Santa 
Cruz Biotechnology), rabbit polyclonal anti-type IV collagen 
antibody (1:200; Santa Cruz Biotechnology), and rabbit poly-
clonal anti-α-SMA antibody (1:100; Santa Cruz Biotechnology). 
For coloration, slides were incubated at room temperature with 
a mixture of 0.05% 3,3´-diaminobenzidine containing 0.01% 
H2O2 and then counterstained with Mayer’s hematoxylin. Nega-
tive control sections were stained under identical conditions 
with a buffer solution that was substituted for the primary anti-
body. A pathologist carried out the histological examinations in 
a blinded manner.
Statistical analysis
Nonparametric analysis was used because of the small sample 
size. Results are expressed as mean ± s.e.m. Multiple compari-
sons were carried out using Wilcoxon’s rank-sum tests and the 
Bonferroni correction. A Kruskal–Wallis test was used to com-
pare more than two groups, followed by a Mann–Whitney U-
test, using a microcomputer-assisted program called SPSS for 
Windows 20.0 (IBM SPSS statistics, Chicago, IL, USA). P value 
< 0.05 was considered statistically significant.
Ethics statement 
All experiments were conducted in accordance with the Na-
tional Institute of Health and guideline after the approval of the 
Korea University institutional animal care and use committee.
RESULTS
Physical and biochemical parameters of experimental 
animals
The physical and biochemical parameters for each group of the 
experimental animals are shown in Table 1. Injection of high 
dose ADX induced dehydration and cachexia in a previous ani-
mal study (12). In our study, ADX administration inhibited wei-
ght gain. Mice with ADX-induced nephropathy displayed a sig-
nificant decrease in body weight compared to the control mice 
four weeks after an 11 mg/kg injection of ADX. At the time of 
sacrifice, mice in the ADX injection group had significantly low-
er body weight than mice in the control group, and LJ1888 ad-
ministration led to recovery of body weight lost during ADX 
treatment. The body weight of LJ1888-treated mice was signifi-
cantly increased compared to that of ADX-injected mice at six 
weeks, despite no significant changes in daily water and food 
intake. Although urine volume tended to increase at two weeks 
and decrease at four weeks after ADX injection compared with 
control mice, there was no significant difference based on LJ1888 
treatment. Kidney weight was significantly lower in ADX-induc-
ed nephropathy than in the control group. However, LJ1888 treat-
ment did not induce any significant change in kidney weight. 
ADX increased the plasma creatinine level significantly, which 
was improved by LJ1888 treatment. 
Effects of LJ1888 administration on urinary excretion of 
protein and albumin in ADX-induced nephropathy
ADX leads to direct toxic injury of the glomerular filtration bar-
rier including podocytes, the glomerular basement membrane 
and glomerular endothelial cells. Podocyte damage induces 
loss of protein and nephrin in the urine (13). In order to investi-
gate the effects of LJ1888 on podocyte injury in ADX-induced 
nephropathy, we checked the urinary excretion of protein and 
Table 1. Physical and biochemical parameters of experimental animals
Parameters Week Control (n = 5) ADX (n = 10) ADX + LJ1888 (n = 10)
Body weight, g 0
4
6
23.20 ± 0.20
27.20 ± 0.49
29.00 ± 0.32
23.09 ± 0.41
24.91 ± 0.37*
20.50 ± 1.09*
22.80 ± 0.33
25.60 ± 0.40†
23.90 ± 1.00*,‡
Daily water intake, g 0
6
9.00 ± 0.45
5.60 ± 0.40
5.12 ± 0.57
6.75 ± 1.25
5.88 ± 0.46
4.40 ± 0.40
Daily food intake, g 0
6
4.20 ± 0.20
4.80 ± 0.37
3.60 ± 0.19
4.25 ± 1.11
4.02 ± 0.24
3.60 ± 0.68
Urine volume, mL/d 0
2
4
6
386.00 ± 88.80
266.00 ± 24.21
880.00 ± 296.61
488.00 ± 63.44
238.33 ± 46.51
414.55 ± 70.60
279.50 ± 83.75
435.00 ± 135.98
556.00 ± 78.09
536.00 ± 83.79†
316.00 ± 65.71
232.00 ± 28.00†
Plasma Cr, mg/dL 6 0.075 ± 0.003 0.116 ± 0.009† 0.082 ± 0.007‡
Kidney/100 g Body weight 6 2.575 ± 0.055 1.816 ± 0.077* 1.727 ± 0.050*
Heart/100 g Body weight 6 0.631 ± 0.016 0.643 ± 0.027 0.591 ± 0.018
Values are expressed as (means ± SEM).
ADX, adriamycin; Cr, creatinine.
*P < 0.01; †P < 0.05 vs. control; ‡P < 0.05 vs. ADX.
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albumin. Urinary protein excretion was significantly increased 
at four and six weeks after ADX injection compared with the 
control group. LJ1888 treatment inhibited urinary protein ex-
cretion during two weeks of treatment in ADX-induced neph-
ropathy (Fig. 1A). In addition, urinary albumin excretion signifi-
cantly increased four and six weeks after ADX injection com-
pared with the control group, and significantly decreased after 
two weeks of LJ1888 treatment in ADX-induced nephropathy 
(Fig. 1B).
Effects of LJ1888 on oxidative stress and urinary nephrin 
excretion in ADX-induced nephropathy
The mechanism of ADX-induced nephropathy occurs in part 
through podocyte injury via oxidative stress. ADX exacerbates 
cellular damage in the renal cortex, inducing renal fibrosis (14). 
Examination of urinary 8-isoprostane excretion and kidney lip-
id peroxidation (LPO) concentration is an approach for diag-
nostic assessment of oxidative stress in the kidney (15). In our 
study, the urinary level of 8-isoprostane markedly increased six 
weeks after ADX injection compared with the control group, 
and significantly decreased after two weeks of LJ1888 treatment 
Fig. 1. Effects of LJ1888 on urinary excretion of protein and albumin in experimental ADX-induced nephropathy. (A) Twenty-four hour urinary protein excretion level. (B) Urinary 
excretion of albumin level. Urinary protein, albumin, and nephrin levels were corrected for urine creatinine levels.
Values are expressed as (means ± SEM).
ADX, adriamycin.
*P < 0.01; †P < 0.05 vs. control; ‡P < 0.001 vs. ADX.
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(Fig. 2A). Likewise, LPO concentration in the kidney was signifi-
cantly increased six weeks after ADX injection compared with 
the control group, but significantly decreased after LJ1888 treat-
ment (Fig. 2B). In addition, we measured urinary nephrin ex-
cretion to determine podocyte injury. As shown in Fig. 2C, each 
group showed no significant difference in urinary nephrin ex-
cretion during four weeks after ADX administration. However, 
nephrin was markedly increased at six weeks after ADX injec-
tion compared with the control group. Interestingly, LJ1888 treat-
ment yielded the greatest inhibitory effects on urinary nephrin 
excretion.
Effects of LJ1888 on proinflammatory and profibrotic 
mechanisms in ADX-induced nephropathy
To determine whether LJ1888 has a protective effect in ADX ne-
phropathy, we next investigated the mRNA expression of proin-
flammatory and profibrotic molecules in renal cortical tissue. 
Gene expression of profibrotic cytokines including type IV col-
lagen, plasminogen activator inhibitor (PAI)-1, macrophage/
monocyte chemoattractant protein (MCP)-1, and NOX4 were 
remarkably increased in ADX-injected mice. On the other hand, 
LJ1888 treatment significantly suppressed the expression of 
PAI-1, MCP-1, and NOX4. TGF-β1 mRNA levels in the renal cor-
tex (Fig. 3A). Similarly, proinflammatory cytokines such as TLR4, 
tumor necrosis factor (TNFα), interleukin (IL)-1β, and interfer-
on (IFN)-γ were highly expressed after ADX administration com-
pared to the control group, and their mRNA expression was sig-
nificantly suppressed after LJ1888 treatment. As expected, A3AR 
mRNA levels significantly increased after ADX injection, but 
did not change significantly after LJ1888 administration (Fig. 
3B). Moreover, western blot analysis confirmed that the renal 
cortical expression of NF-κB, TGF-β1, and NOX4 were all mark-
edly induced in ADX-injected mice. On the other hand, LJ1888 
significantly reduced the expression of all these proteins. TLR4 
did not differ among the three groups in the kidney (Fig. 3C).
Effects of LJ1888 on histomorphological changes in ADX-
induced nephropathy 
Fig. 4 shows representative renal pathology and immunohisto-
chemical staining for each group of experimental animals at 
the time of sacrifice. PAS and Masson’s trichrome staining dem-
onstrated that glomerular and tubulointerstitial damage includ-
Fig. 3. Effects of LJ1888 on inflammation and fibrosis in ADX-induced nephropathy. (A and B) Effects of LJ1888 on the expression of inflammatory and fibrotic cytokines. (C) 
Representative western blots of NF-κB, TGF-β1, NOX4, and TLR4 in the kidney and quantitative analysis scoring of western blot.
Values are expressed as (means ± SEM).
ADX, adriamycin; Col-4, type IV collagen; PAI-1, plasminogen activator inhibitor-1; MCP-1, macrophage/monocyte chemoattractant peptide-1; TGF-β1, transforming growth 
factor-β1; NOX-4, NADPH oxidase 4; TLR-4,Toll-like receptor 4; A3AR, A3 adenosine receptor; TNFα, tumor necrosis α; IL-1β, interleukine-1β; IFN-γ, interferon-γ; NF-κB, nu-
clear factor-κB.
*P < 0.05; †P < 0.01 vs. control; ‡P < 0.05; §P < 0.001; llP < 0.01 vs. ADX.
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ing glomerulosclerosis, excessive collagen deposition, intersti-
tial fibrosis, and tubular atrophy were dramatically increased in 
ADX-induced nephropathy. The glomeruli had much more se-
vere pathological changes than the tubulointerstitium in ADX-
induced nephropathy. ADX led to development of progressive 
glomerulosclerosis and demonstrated increased accumulation 
of type I collagen, type IV collagen, TGF-β1, and α-SMA in the 
glomeruli. In contrast, LJ1888 administration significantly ame-
liorated severe damage lesions of glomerulosclerosis. Infiltra-
tion of inflammatory cells such as macrophages and T lympho-
cytes in the renal glomeruli is an important pathological finding 
in the early progression of ADX-induced nephropathy (12). F4/80 
is macrophage specific to the inflammatory process. F4/80 stain-
ing demonstrated that macrophage infiltration in the glomeruli 
was markedly increased after ADX injection and dramatically 
recovered with LJ1888 treatment. Nephrin has important effects 
Fig. 4. Representative renal histological and immunohistochemical staining in experimental models at the time of sacrifice. Representative sections show that the histological 
changes and immunohistochemical staining for PAS, F4/80, Masson’s trichrome and α-SMA, nephrin, type I collagen, TGF-β1, and type IV collagen are increased in ADX-in-
duced nephropathy and decreased after treatment with LJ1888. Original magnification × 400.
ADX, adriamycin; PAS, periodic acid-Schiff; α-SMA, α-smooth muscle actin; TGF-β1, transforming growth factor-β1.
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in controlling the integrity and functions of the podocyte slit di-
aphragm structure (16). In a previous study, ADX induced di-
rect toxic damage to the podocytes and loss of nephrin in urine 
(13). Immunohistochemical staining revealed that the numbers 
of nephrin-positive cells were dramatically decreased in the 
glomeruli of ADX-injected mice and were significantly restored 
by LJ1888 treatment. As shown in Fig. 5, quantitative analysis 
with immunohistochemical staining demonstrated those re-
sults.
DISCUSSION
In the present study, we first demonstrated that a highly selec-
tive A3AR antagonist reduced proteinuria and albuminuria, 
improved renal function, and recovered histomorphological 
changes that occurred during ADX-induced nephropathy. We 
concluded that this selective A3AR antagonist had a notable ef-
fect on urinary nephrin excretion and its glomerular expres-
sion, which may prevent podocyte injury. Clinically, protein-
uria is the most characteristic manifestation of podocyte injury 
in kidney disease. We used ADX to develop the renal glomeru-
lar injury. ADX induces proteinuria and nephrin loss in urine 
by injuring the glomerular filtration barrier, decreasing glomer-
ular endothelial cell thickness and glomerular charge selectivity 
and increasing podocyte foot process effacement (17,18). The 
Fig. 5. Quantitation of immunohistochemical staining. (A) Glomerulosclerosis index, (B) F4/80 positive cell staining score, (C) Tubulointerstitial fibrosis index, (D) Quantitation of 
immunohistochemical staining of nephrin, type I Collagen, TGF-β1 and Type 4 collagen.
Values are expressed as (means ± SEM).
ADX, adriamycin.
*P < 0.01 vs. control; †P < 0.001; ‡P < 0.01 vs. ADX.
Gl
om
er
ul
os
cl
er
os
is
 in
de
x
 Control ADX ADX+LJ1888
2.0
1.5
1.0
0.5
0
*
*,†
Tu
bu
lo
in
te
rs
tit
ia
l fi
br
os
is
 in
de
x
 Control ADX ADX+LJ1888
1.5
1.0
0.5
0
*
*,‡
F4
/8
0 
(+
) c
el
ls
/H
PF
 Control ADX ADX + LJ1888
80
60
40
20
0
*
*,†
Qu
an
tit
at
io
n 
of
 
im
m
un
oh
is
to
ch
em
ic
al
 s
ta
in
in
g
 Nephrin Type I Col TGFβ1 Type IV Col
2.5
2.0
1.5
1.0
0.5
0
*
*,†
* *
*,†
*,†
*,†
Control
ADX
ADX + LJ1888
*
A B
C D
renal histological changes due to ADX appear about one week 
after ADX administration and degenerate into severe injury by 
four weeks (19). 
 Adenosine has various effects in the kidneys, including the 
regulation of renin secretion, glomerular filtration rate, renal 
vascular tone, tubular glomerular feedback, fluid and electro-
lyte transport of the tubular and collecting duct system, and 
metabolic renal function. The concentration of extracellular 
adenosine is maintained at approximately 100 nM under nor-
mal conditions and rapidly increases during renal cell damage 
(20). A previous study demonstrated that long-term exposure 
to high concentrations of adenosine induced secretion of intra-
cellular proinflammatory cytokines, activation of fibroblasts, 
and deposition of collagen in the extracellular matrix (21). A re-
cent study showed that an increase in adenosine levels led to 
ischemic renal fibrosis and finally induced renal interstitial fi-
brosis in renal cell damage in the unilateral ureteral obstruction 
model (22).
 Activation of A3AR by adenosine leads to a decrease in ade-
nylyl cyclase activity and cAMP production, which induce stim-
ulation of phospholipase C (PLC) activity, Ca2+ mobilization, 
and phosphorylation of phosphatidylinositol 3-kinase (PI3K) 
and AKT. AKT modulates the mitogen-activated protein kinase 
(MAPK) family including c-JUN N-terminal kinase (JNK), extra-
cellular signal-regulated kinase (ERK), and p38 MAPK (6). There-
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fore, A3AR activation stimulates p38 MAPK phosphorylation, 
leading to decreased hypoxic damage of cardiomyocytes (23). 
On the other hand, A3AR activation suppresses the p38 MAPK 
pathway, leading to down-regulation of the inflammatory sta-
tus in human synoviocytes (24). A3AR has different effects in 
different cell types, such as cell proliferation and cell death, which 
may be related to PI3K/AKT and ERK1/2 pathway crosstalk (25). 
Many studies have shown the biologic functions and therapeu-
tic applications of A3AR and A3AR antagonists in the brain, heart, 
lung, and immune system (6). 
 LJ1888 dramatically suppressed the urinary excretion of neph-
rin. In immunohistochemical staining, the numbers of neph-
rin-positive cells were dramatically decreased by ADX and sig-
nificantly restored by LJ1888 treatment. Nephrin is one of the 
molecules that constitute the podocyte slit diaphragm and it is 
involved the maturation of podocytes during glomerular devel-
opment (26). Nephrin induces phosphorylation and activation 
of the PI3K-dependent AKT downstream signaling pathway. 
Several AKT targets bind to the phosphorylation-dependent 
14-3-3 proteins, which are involved in the control of cell growth, 
migration, proliferation, and apoptosis. Nephrin-induced PI3K/ 
AKT signaling plays a preventative role in podocyte apoptosis 
(27). A3AR transmits a cellular proliferation signal through the 
PI3K/AKT signaling pathway. Stimulated AKT is able to phos-
phorylate many downstream substrates such as Raf. Therefore, 
by blocking Raf through AKT activation and inducing cell death, 
A3AR inhibits the MAPK pathway, including RAS, Raf, MEK1/2, 
and ERK1/2 (25). A3AR gene expression in renal cortical tissue 
was dramatically increased in ADX-induced nephropathy. Al-
though LJ1888 did not suppress A3AR gene expression, LJ1888 
inhibited A3AR-associated PI3K/AKT and RAS/RAF/MEK/ERK 
downstream pathways, protecting podocytes from apoptosis. 
Additional studies are required to demonstrate the interaction 
of A3AR and nephrin downstream pathways. 
 There is a considerable body of evidence regarding oxidative 
stress in various kidney diseases. In ADX-induced nephropa-
thy, oxidative stress and inflammation are important mecha-
nisms of progressive proteinuric nephropathy leading to renal 
fibrosis (13). Renal tissue hypoxia induces the elevation of ade-
nosine levels, leading to renal fibrosis (22). Oxidative stress in-
duces stimulation of TGF-β1 expression and production of ex-
tracellular matrix, leading to glomerular and tubulointerstitial 
fibrosis. The MAPK family signaling is activated by oxidative 
stress in renal cells. The JNK pathway is associated with pro-
gression of renal fibrosis and tubular apoptosis (28). Stimula-
tion of the ERK pathway is related to proliferative glomerulone-
phritis (29). Activation of the p38 MAPK pathway by IL-1, TNF-α, 
and TFG-β1 induces extracellular matrix accumulation, leading 
to tubulointerstitial fibrosis (30). A previous study demonstrat-
ed that LJ1888 significantly suppressed JNK and ERK phosphor-
ylation during TGF-β1 upregulation in the kidney (9). In this 
study, we observed that LJ1888 treatment attenuated the in-
creased urinary excretion of 8-isoprostane and the increased 
LPO concentration in kidney tissue after ADX injection. 
 In addition, mRNA expression of proinflammatory molecules 
including TLR4, TNFα, IL-1β, and IFN-γ increased in ADX-in-
duced nephropathy, and dramatically recovered during LJ1888 
treatment. The TLR4/NK-κB pathway is considered to be an 
important link between inflammation and oxidative stress in 
kidney disease (31,32). Gene expression of profibrotic mole-
cules including type IV collagen, PAI-1, MCP-1, TGF-β1, and 
NOX4, as wells as NF-κB protein, were increased by ADX and 
significantly decreased by LJ1888. Renal histological and im-
munohistochemical staining demonstrated similar results con-
sistently. Type I collagen, type IV collagen, TGF-β1, and α-SMA 
accumulation in the fibrotic area of the renal glomeruli were 
increased in ADX-induced nephropathy, as was macrophage 
infiltration. Those profibrotic and proinflammatory molecules 
were genetically suppressed significantly by LJ1888 administra-
tion. The extensive glomerular and tubulointerstitial damage, 
including glomerulosclerosis, excessive collagen deposition, 
interstitial fibrosis, and tubular atrophy, were dramatically in-
creased in ADX-induced nephropathy. In contrast, LJ1888 ad-
ministration significantly ameliorated severe damage lesions in 
both the glomerular and tubular compartments. We suggest 
that LJ 1888 ameliorated oxidative stress, inflammation, and fi-
brosis in ADX-induced nephropathy through antioxidative me-
chanisms via A3AR.
 In summary, we are the first to show that LJ1888, a highly se-
lective A3AR antagonist, exhibits renoprotective effects by ame-
liorating podocyte injury, oxidative stress, inflammation, glo-
merulosclerosis, and tubulointerstitial fibrosis in ADX-induced 
nephropathy. Treatment with LJ1888 induced renoprotective 
effects by attenuating podocyte injury through decreased uri-
nary excretion of nephrin. Therefore, we suggest that LJ1888 
could be a new therapeutic drug for proteinuric renal disease. 
We recommend further study of LJ1888 in progressive renal dis-
ease to demonstrate its therapeutic effect more clearly.
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